Adakveo
Drug name: Adakveo | Dosage form: Injection (intravenous; 100 mg/10 mL [10 mg/mL]) | Approval year: 2019 | Company: Novartis Pharmaceuticals Corporation., East Hanover, NJ | Class: Selectin blockers | System: Blood
Indications
- Indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
Document title: Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404495/pdf/jbm-15-435.pdf Document source: Journal of Blood Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel. Document link: https://link.springer.com/article/10.1007/s00277-024-05736-6 Document source: Annals of Hematology Document type: Clinical Practice Guidelines Document year: 2024
Document title: Adakveo (crizanlizumab-tmca) Prescribing Information. Document link: https://www.novartis.com/us-en/sites/novartis_us/files/adakveo.pdf Document source: Novartis Pharmaceuticals Corporation., East Hanover, NJ Document type: Product Monograph / Prescribing Information Document year: 2024
Document title: The Role of Non-genetic Therapies to Reduce the Incidence of Sickle Cell Crisis: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469705/pdf/cureus-0015-00000042785.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Emerging Therapies for the Management of Pain and Vaso-Occlusive Crises in Patients With Sickle Cell Disease: A Systematic Review of Randomized Controlled Trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204617/pdf/cureus-0015-00000038014.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Genotypic and Phenotypic Composition of Sickle Cell Disease in the Arab Population - A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961577/pdf/pgpm-16-133.pdf Document source: Pharmacogenomics and Personalized Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187358/pdf/cureus-0014-00000024920.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500297/pdf/bmjopen-2019-034147.pdf Document source: BMJ Open Document type: Systematic Reviews / Meta-Analyses Document year: 2020
Document title: Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease Document link: https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.2409 Document source: Pharmacotherapy Document type: Systematic Reviews / Meta-Analyses Document year: 2020
Document title: Therapeutic class overview: sickle cell anemia agents. Document link: https://www.medicaid.nv.gov/Downloads/provider/Sickle_Cell_Anemia_Agents_2020-0319.pdf Document source: OptumRx Document type: Clinical Practice Guidelines Document year: 2020
Ferriprox
Drug name: Ferriprox | Dosage form: Tablet (oral; 500 mg, 1000 mg) | Approval year: 2011 | Company: Chiesi USA, Inc., Cary, NC | Class: Iron chelators | System: Blood
Indications
- Indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias.
Document title: The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10835961/pdf/12955_2023_Article_2221.pdf Document source: Health and Quality of Life Outcomes Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9987409/pdf/CD012349.pdf Document source: The Cochrane Database of Systematic Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10032438/pdf/10.1177_26330040221139872.pdf Document source: Therapeutic Advances in Rare Disease Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8213658/pdf/12311_2020_Article_1222.pdf Document source: Cerebellum Document type: Systematic Reviews / Meta-Analyses Document year: 2021
Document title: Ferriprox (deferiprone) Prescribing Information. Document link: https://resources.chiesiusa.com/Ferriprox/FERRIPROX_PI_US.pdf Document source: Chiesi USA, Inc., Cary, NC Document type: Product Monograph / Prescribing Information Document year: 2021